The majority of derivatives inhibit AChE more efficiently than BuChE and are comparable or superior to rivastigmine—an established cholinesterases inhibitor used in the treatment of Alzheimer’s disease. This evidence concerns the gene ACHE and early-onset autosomal dominant Alzheimer disease.